Molecular-targeted therapies: Lessons from years of clinical development

Cancer Treatment Reviews

Volumn 34, Issue 1, 2008, Pages 61-80

  Rosa, Daniela D ^a,b   Ismael, Gustavo ^a,c   Lago, Lissandra Dal ^a,d   Awada, Ahmad ^a,d  

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c Hospital Amaral Carvalho   (Brazil)

^d FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Anticancer drugs; Drug development; Molecular targeted therapies; New drugs

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CAPECITABINE; CETUXIMAB; CYTOTOXIC AGENT; ERLOTINIB; EVEROLIMUS; FLUOROPYRIMIDINE; GEFITINIB; GEMCITABINE; HORMONE; IMATINIB; INTERFERON; IRINOTECAN; LAPATINIB; LETROZOLE; LONAFARNIB; OXALIPLATIN; PANITUMUMAB; PLACEBO; PLATINUM COMPLEX; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; UNINDEXED DRUG;

ACNE; ADJUVANT THERAPY; BREAST CANCER; CANCER HORMONE THERAPY; CANCER STEM CELL; CANCER THERAPY; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENTIATION; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GENETIC TRANSCRIPTION; HEAD AND NECK CANCER; HEART DISEASE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MACULOPAPULAR RASH; MALIGNANT NEOPLASTIC DISEASE; MICROENVIRONMENT; MONOTHERAPY; NAUSEA; NONHUMAN; PHENOTYPE; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SOLID TUMOR; VALIDATION PROCESS; VOMITING;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION;

EID: 38649109498     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2007.07.019     Document Type: Review

References (262)

1. Green M.R. Targeting targeted therapy. N Engl J Med. 350 21 (2004) 2191-2193
2. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 344 14 (2001) 1031-1037
3. van Oosterom A.T., Judson I., Verweij J., Stroobants S., Donato di Paola E., Dimitrijevic S., et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet. 358 9291 (2001) 1421-1423
4. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 11 (2001) 783-792
5. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 16 (2005) 1659-1672
6. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer Jr. C.E., Davidson N.E., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 16 (2005) 1673-1684
7. Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., Alanko T., Kataja V., Asola R., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354 8 (2006) 809-820
8. Arteaga C.L., and Baselga J. Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?. Cancer Cell 5 6 (2004) 525-531
9. Newell D.R. How to develop a successful cancer drug-molecules to medicines or targets to treatments?. Eur J Cancer 41 5 (2005) 676-682
10. Herman J.G., and Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349 21 (2003) 2042-2054
11. Krause D.S., and Van Etten R.A. Tyrosine kinases as targets for cancer therapy. N Engl J Med 353 2 (2005) 172-187
12. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293 5531 (2001) 876-880
13. Su D., Ma S., Liu P., Jiang Z., Lv W., Zhang Y., et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer 56 2 (2007) 281-288
14. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 4905 (1989) 707-712
15. Tandon A.K., Clark G.M., Chamness G.C., Ullrich A., and McGuire W.L. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7 8 (1989) 1120-1128
16. O'Reilly S.M., Barnes D.M., Camplejohn R.S., Bartkova J., Gregory W.M., and Richards M.A. The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer 63 3 (1991) 444-446
17. Paik S., Hazan R., Fisher E.R., Sass R.E., Fisher B., Redmond C., et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 8 1 (1990) 103-112
18. Toikkanen S., Helin H., Isola J., and Joensuu H. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol 10 7 (1992) 1044-1048
19. Deininger M.W., Goldman J.M., Lydon N., and Melo J.V. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90 9 (1997) 3691-3698
20. Faderl S., Talpaz M., Estrov Z., O'Brien S., Kurzrock R., and Kantarjian H.M. The biology of chronic myeloid leukemia. N Engl J Med 341 3 (1999) 164-172
21. Goldman J.M., and Melo J.V. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344 14 (2001) 1084-1086
22. Goldman J.M. Tyrosine-kinase inhibition in treatment of chronic myeloid leukaemia. Lancet 355 9209 (2000) 1031-1032
23. Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M., et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344 14 (2001) 1038-1042
24. Joensuu H., Roberts P.J., Sarlomo-Rikala M., Andersson L.C., Tervahartiala P., Tuveson D., et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344 14 (2001) 1052-1056
25. O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348 11 (2003) 994-1004
26. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2 5 (1996) 561-566
27. Kantarjian H., Sawyers C., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C., et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346 9 (2002) 645-652
28. Talpaz M., Silver R.T., Druker B., et al. Gleevec (formerly STI571): an active drug in patients with Ph+ chronic myeloid leukemia in accelerated phase - updated results of a phase II study. Blood 98 (2001) 845a [Abstract 3509]
29. Sawyers C.L., Hochhaus A., Feldman E., et al. Gleevec/Glivec (imatinib mesylate, STI-571) in patients with chronic myeloid leukemia (CML) in myeloid blast crisis: updated results of a phase II study. Blood (2001) 845a [Abstract 3510]
30. Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 7 (2002) 472-480
31. Nilsson B., Sjolund K., Kindblom L.G., Meis-Kindblom J.M., Bumming P., Nilsson O., et al. Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). Br J Cancer 96 11 (2007) 1656-1658
32. Perez-Soler R. HER1/EGFR targeting: refining the strategy. Oncologist 9 1 (2004) 58-67
33. Sedlacek H.H. Kinase inhibitors in cancer therapy: a look ahead. Drugs 59 3 (2000) 435-476
34. Wells A. EGF receptor. Int J Biochem Cell Biol 31 6 (1999) 637-643
35. Jones J.T., Akita R.W., and Sliwkowski M.X. Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett 447 2-3 (1999) 227-231
36. Semba K., Kamata N., Toyoshima K., and Yamamoto T. A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci USA 82 19 (1985) 6497-6501
37. Hackel P.O., Zwick E., Prenzel N., and Ullrich A. Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol 11 2 (1999) 184-189
38. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2 2 (2001) 127-137
39. Salomon D.S., Brandt R., Ciardiello F., and Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19 3 (1995) 183-232
40. Herbst R.S., Prager D., Hermann R., Fehrenbacher L., Johnson B.E., Sandler A., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23 25 (2005) 5892-5899
41. Giaccone G., Herbst R.S., Manegold C., Scagliotti G., Rosell R., Miller V., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 22 5 (2004) 777-784
42. Herbst R.S., Giaccone G., Schiller J.H., Natale R.B., Miller V., Manegold C., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 22 5 (2004) 785-794
43. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21 12 (2003) 2237-2246
44. Kris M.G., Natale R.B., Herbst R.S., Lynch Jr. T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. Jama 290 16 (2003) 2149-2158
45. Tsao M.S., Sakurada A., Cutz J.C., Zhu C.Q., Kamel-Reid S., Squire J., et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 353 2 (2005) 133-144
46. Cappuzzo F., Hirsch F.R., Rossi E., Bartolini S., Ceresoli G.L., Bemis L., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97 9 (2005) 643-655
47. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 5676 (2004) 1497-1500
48. Eberhard D.A., Johnson B.E., Amler L.C., Goddard A.D., Heldens S.L., Herbst R.S., et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23 25 (2005) 5900-5909
49. West H.L., Franklin W.A., McCoy J., Gumerlock P.H., Vance R., Lau D.H., et al. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol 24 12 (2006) 1807-1813
50. Thatcher N., Chang A., Parikh P., Rodrigues Pereira J., Ciuleanu T., von Pawel J., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366 9496 (2005) 1527-1537
51. Hirsch F.R., Varella-Garcia M., Bunn Jr. P.A., Franklin W.A., Dziadziuszko R., Thatcher N., et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 24 31 (2006) 5034-5042
52. Perez-Soler R., Chachoua A., Hammond L.A., Rowinsky E.K., Huberman M., Karp D., et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22 16 (2004) 3238-3247
53. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 2 (2005) 123-132
54. Prewett M.C., Hooper A.T., Bassi R., Ellis L.M., Waksal H.W., and Hicklin D.J. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 8 5 (2002) 994-1003
55. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 4 (2004) 337-345
56. Xu Y., and Villalona-Calero M.A. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 13 12 (2002) 1841-1851
57. Chen Z.S., Furukawa T., Sumizawa T., Ono K., Ueda K., Seto K., et al. ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol 55 5 (1999) 921-928
58. Chu X.Y., Suzuki H., Ueda K., Kato Y., Akiyama S., and Sugiyama Y. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines. J Pharmacol Exp Ther 288 2 (1999) 735-741
59. Naruse I., Ohmori T., Ao Y., Fukumoto H., Kuroki T., Mori M., et al. Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo. Int J Cancer 98 2 (2002) 310-315
60. Sclabas G.M., Fujioka S., Schmidt C., Fan Z., Evans D.B., and Chiao P.J. Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-kappaB signaling pathway with the anti-epidermal growth factor antibody IMC-C225. J Gastrointest Surg 7 1 (2003) 37-43 discussion
61. Bandyopadhyay D., Mandal M., Adam L., Mendelsohn J., and Kumar R. Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem 273 3 (1998) 1568-1573
62. Huang S.M., and Harari P.M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6 6 (2000) 2166-2174
63. Saltz L., Kies M.S., Abbruzzese J.L., Azarnia N., and Needle M.N. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. J Clin Oncol 22 (2003) 204 [Abstract]
64. Vanhoefer U., Tewes M., Rojo F., Dirsch O., Schleucher N., Rosen O., et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 22 1 (2004) 175-184
65. Baselga J., Trigo J.M., Bourhis J., Tortochaux J., Cortes-Funes H., Hitt R., et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23 24 (2005) 5568-5577
66. Herbst R.S., Arquette M., Shin D.M., Dicke K., Vokes E.E., Azarnia N., et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 23 24 (2005) 5578-5587
67. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 6 (2006) 567-578
68. Hanna N., Lilenbaum R., Ansari R., Lynch T., Govindan R., Janne P.A., et al. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 24 33 (2006) 5253-5258
69. Yang X.D., Jia X.C., Corvalan J.R., Wang P., and Davis C.G. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 38 1 (2001) 17-23
70. Van Cutsem E., Peeters M., Siena S., Humblet Y., Hendlisz A., Neyns B., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25 13 (2007) 1658-1664
71. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 4785 (1987) 177-182
72. Carter P., Presta L., Gorman C.M., Ridgway J.B., Henner D., Wong W.L., et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89 10 (1992) 4285-4289
73. Pegram M., Hsu S., Lewis G., Pietras R., Beryt M., Sliwkowski M., et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18 13 (1999) 2241-2251
74. Eisenhauer E.A. From the molecule to the clinic-inhibiting HER2 to treat breast cancer. N Engl J Med 344 11 (2001) 841-842
75. Slamon D., Eiermann W., Robert N., et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 94 (2005) S5 [Abstract]
76. Xia W., Mullin R.J., Keith B.R., Liu L.H., Ma H., Rusnak D.W., et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21 41 (2002) 6255-6263
77. Rusnak D.W., Lackey K., Affleck K., Wood E.R., Alligood K.J., Rhodes N., et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 1 2 (2001) 85-94
78. Burris III H.A., Hurwitz H.I., Dees E.C., Dowlati A., Blackwell K.L., O'Neil B., et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23 23 (2005) 5305-5313
79. Gomez H.L., Chavez M.A., and Doval D.C. A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer. J Clin Oncol 23 (2005) 203s [Abstract]
80. Kallioniemi O.P., Holli K., Visakorpi T., Koivula T., Helin H.H., and Isola J.J. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 49 5 (1991) 650-655
81. Lin N.U., Carey L.A., Liu M.C., et al. Phase II trial of lapatinib for brain metastasis with HER2+ breast cancer. J Clin Oncol 24 18S (2006) 3s [Abstract]
82. Konecny G.E., Pegram M.D., Venkatesan N., Finn R., Yang G., Rahmeh M., et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66 3 (2006) 1630-1639
83. Storniolo A.M., Burris III H.A., Overmoyer B., et al. A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with trastuzumab. Breast Cancer Res Treat 4 Suppl. 1 (2005) A-1040 [Abstract]
84. Spector N.L., Blackwell K., Hurley J., et al. EGF103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC) clinical activity and biological predictors of response. J Clin Oncol 18S (2006) 3s [Abstract 502]
85. Geyer C.E., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355 26 (2006) 2733-2743
86. Piccart-Gebhart MJ, Perez EA, Baselga J, et al. ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study [BIG 2-06/N063D/EGF106708]: a phase III study of HER2-overexpressing early breast cancer (BC). Abstract P1118. In: St. Gallen breast cancer conference; 2007.
87. Abidoye O.O., Cohen E.E., Wong S.J., et al. A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 24 18S (2006) [Abstract 5568]
88. Safran H., Iannitti D., Minner T., et al. GW572016, gemcitabine and GW572016, gemcitabine, oxaliplatin, a two-stage, phase I study for advanced pancreaticobiliary cancer. J Clin Oncol 24 18S (2006) 4002 [Abstract 4002]
89. Iqbal S., Goldman B., Lenz H.J., Fenoglio-Preiser C.M., and Blanke C.D. S0413: a phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients (pts) with advanced or metastatic gastric cancer. J Clin Oncol 25 18S (2007) [Abstract 4621]
90. Johnston S.R. Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer. Clin Cancer Res 12 3 Pt 2 (2006) 1061s-1068s
91. Hudson C.C., Liu M., Chiang G.G., Otterness D.M., Loomis D.C., Kaper F., et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22 20 (2002) 7004-7014
92. Cho D., Signoretti S., Regan M., Mier J.W., and Atkins M.B. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res 13 2 Pt 2 (2007) 758s-763s
93. Yu K., Toral-Barza L., Discafani C., Zhang W.G., Skotnicki J., Frost P., et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 8 3 (2001) 249-258
94. Raymond E., Alexandre J., Faivre S., Vera K., Materman E., Boni J., et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22 12 (2004) 2336-2347
95. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 22 (2007) 2271-2281
96. Boulay A., Rudloff J., Ye J., Zumstein-Mecker S., O'Reilly T., Evans D.B., et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 11 14 (2005) 5319-5328
97. ®), investigating safety and pharmacokinetics in patients with advanced breast cancer stable or slowly progressing on letrozole. Abstract A6043. In: Proceedings of San Antonio breast cancer symposium; 2004.
98. Peyssonnaux C., and Eychene A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 93 1-2 (2001) 53-62
99. Marais R., Light Y., Paterson H.F., Mason C.S., and Marshall C.J. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J Biol Chem 272 7 (1997) 4378-4383
100. Khosravi-Far R., and Der C.J. The Ras signal transduction pathway. Cancer Metastasis Rev 13 1 (1994) 67-89
101. End D.W., Smets G., Todd A.V., Applegate T.L., Fuery C.J., Angibaud P., et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 61 1 (2001) 131-137
102. Sepp-Lorenzino L., Ma Z., Rands E., Kohl N.E., Gibbs J.B., Oliff A., et al. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res 55 22 (1995) 5302-5309
103. Liu M., Bryant M.S., Chen J., Lee S., Yaremko B., Lipari P., et al. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res 58 21 (1998) 4947-4956
104. Kelland L.R., Smith V., Valenti M., Patterson L., Clarke P.A., Detre S., et al. Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. Clin Cancer Res 7 11 (2001) 3544-3550
105. Johnston S.R., Hickish T., Ellis P., Houston S., Kelland L., Dowsett M., et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol 21 13 (2003) 2492-2499
106. Adjei A.A., Mauer A., Bruzek L., Marks R.S., Hillman S., Geyer S., et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J Clin Oncol 21 9 (2003) 1760-1766
107. Heymach J.V., Johnson D.H., Khuri F.R., Safran H., Schlabach L.L., Yunus F., et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer. Ann Oncol 15 8 (2004) 1187-1193
108. Rao S., Cunningham D., de Gramont A., Scheithauer W., Smakal M., Humblet Y., et al. Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol 22 19 (2004) 3950-3957
109. Van Cutsem E., Karasek P., Oettle H., et al. Phase III trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine + placebo in advanced pancreatic cancer. J Clin Oncol 21 (2002) 517 [Abstract]
110. Lancet J.E., Karp J.E., Gotlib L., et al. ZarnestraTM (R115777) in previously untreated poor-risk AML and MDS: preliminary results of a phase II trial. Blood 100 (2002) 560a [Abstract]
111. Awada A., Eskens F.A., Piccart M., Cutler D.L., van der Gaast A., Bleiberg H., et al. Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours. Eur J Cancer 38 17 (2002) 2272-2278
112. Adjei A.A., Erlichman C., Davis J.N., Cutler D.L., Sloan J.A., Marks R.S., et al. A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res 60 7 (2000) 1871-1877
113. Eskens F.A., Awada A., Cutler D.L., de Jonge M.J., Luyten G.P., Faber M.N., et al. Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. J Clin Oncol 19 4 (2001) 1167-1175
114. Winquist E., Moore M.J., Chi K.N., Ernst D.S., Hirte H., North S., et al. A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer. Urol Oncol 23 3 (2005) 143-149
115. Sharma S., Kemeny N., Kelsen D.P., Ilson D., O'Reilly E., Zaknoen S., et al. A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. Ann Oncol 13 7 (2002) 1067-1071
116. Yang C.H., Kies M.S., Glisson B., et al. A phase II study of lonafarnib (SCH66336) in patients with chemo-refractory advanced head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 24 5565 (2005) [Abstract]
117. Appels N.M., Beijnen J.H., and Schellens J.H. Development of farnesyl transferase inhibitors: a review. Oncologist 10 8 (2005) 565-578
118. Whyte D.B., Kirschmeier P., Hockenberry T.N., Nunez-Oliva I., James L., Catino J.J., et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 272 22 (1997) 14459-14464
119. Mitsiades C.S., Mitsiades N., Hideshima T., Richardson P.G., and Anderson K.C. Proteasome inhibition as a new therapeutic principle in hematological malignancies. Curr Drug Targets 7 10 (2006) 1341-1347
120. Sommer T., Jarosch E., and Lenk U. Compartment-specific functions of the ubiquitin-proteasome pathway. Rev Physiol Biochem Pharmacol 142 (2001) 97-160
121. Adams J. Proteasome inhibitors as new anticancer drugs. Curr Opin Oncol 14 6 (2002) 628-634
122. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5 5 (2004) 417-421
123. LeBlanc R., Catley L.P., Hideshima T., Lentzsch S., Mitsiades C.S., Mitsiades N., et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 62 17 (2002) 4996-5000
124. Teicher B.A., Ara G., Herbst R., Palombella V.J., and Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 5 9 (1999) 2638-2645
125. Pervan M., Pajonk F., Sun J.R., Withers H.R., and McBride W.H. Molecular pathways that modify tumor radiation response. Am J Clin Oncol 24 5 (2001) 481-485
126. Aghajanian C., Soignet S., Dizon D.S., Pien C.S., Adams J., Elliott P.J., et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8 8 (2002) 2505-2511
127. Orlowski R.Z., Stinchcombe T.E., Mitchell B.S., Shea T.C., Baldwin A.S., Stahl S., et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20 22 (2002) 4420-4427
128. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348 26 (2003) 2609-2617
129. Zangari M., Barlogie B., Hollmig K., et al. Marked activity of Velcade plus thalidomide (V + T) in advanced and refractory multiple myeloma (MM). Blood 104 (2004) 413a [Abstract]
130. Yang C.H., Gonzalez-Angulo A.M., Reuben J.M., Booser D.J., Pusztai L., Krishnamurthy S., et al. Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol 17 5 (2006) 813-817
131. Stevenson J.P., Nho C.W., Johnson S.W., et al. Effects of bortezomib (PS-341) on NF-αB activation in peripheral blood mononuclear cells (PBMCs) of advanced non-small cell lung cancer (NSCLC) patients: a phase II/pharmacodynamic trial. J Clin Oncol 23 (2004) 649a [Abstract]
132. Albanell J., Baselga J., Awada A., et al. Phase I study of bortezomib in combination with docetaxel in anthracycline-pretreated advanced breast cancer. J Clin Oncol (2003) [Abstract 63]
133. Cardoso F., Azambuja E., Bernard C., et al. A phase I, open label, dose-escalating study of the proteasome inhibitor PS-341 (VELCADE®) in combination with two schedules of trastuzumab, in patients with advanced breast cancer (ABC) that overexpresses HER-2. Eur J Cancer 4 (2006) 173 [Abstract 429]
134. Goy A., Younes A., McLaughlin P., Pro B., Romaguera J.E., Hagemeister F., et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23 4 (2005) 667-675
135. O'Connor O.A., Wright J., Moskowitz C., Muzzy J., MacGregor-Cortelli B., Stubblefield M., et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 23 4 (2005) 676-684
136. Belch A., Kouroukis C.T., Crump M., Sehn L., Gascoyne R.D., Klasa R., et al. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 18 1 (2007) 116-121
137. Meyerson M., Enders G.H., Wu C.L., Su L.K., Gorka C., Nelson C., et al. A family of human cdc2-related protein kinases. Embo J 11 8 (1992) 2909-2917
138. Sherr C.J. Cancer cell cycles. Science 274 5293 (1996) 1672-1677
139. Shapiro G.I., and Harper J.W. Anticancer drug targets: cell cycle and checkpoint control. J Clin Invest 104 12 (1999) 1645-1653
140. Senderowicz A.M., and Sausville E.A. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 92 5 (2000) 376-387
141. Mani S., Wang C., Wu K., Francis R., and Pestell R. Cyclin-dependent kinase inhibitors: novel anticancer agents. Expert Opin Investig Drugs 9 8 (2000) 1849-1870
142. Shapiro G.I. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin Cancer Res 10 12 Pt 2 (2004) 4270s-4275s
143. Schang L.M. Advances on cyclin-dependent kinases (CDKs) as novel targets for antiviral drugs. Curr Drug Targets Infect Disord 5 1 (2005) 29-37
144. Burdette-Radoux S., Tozer R.G., Lohmann R.C., Quirt I., Ernst D.S., Walsh W., et al. Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Invest New Drugs 22 3 (2004) 315-322
145. Morris D.G., Bramwell V.H., Turcotte R., Figueredo A.T., Blackstein M.E., Verma S., et al. A phase II study of flavopiridol in patients with previously untreated advanced soft tissue sarcoma. Sarcoma 2006 (2006) 64374
146. Shapiro G.I., Supko J.G., Patterson A., Lynch C., Lucca J., Zacarola P.F., et al. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res 7 6 (2001) 1590-1599
147. Bible K.C., and Kaufmann S.H. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res 57 16 (1997) 3375-3380
148. Byrd J.C., Lin T.S., Dalton J.T., Wu D., Phelps M.A., Fischer B., et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109 2 (2007) 399-404
149. Schwartz G.K., O'Reilly E., Ilson D., Saltz L., Sharma S., Tong W., et al. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol 20 8 (2002) 2157-2170
150. Tan A.R., Yang X., Berman A., Zhai S., Sparreboom A., Parr A.L., et al. Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer. Clin Cancer Res 10 15 (2004) 5038-5047
151. Bible K.C., Lensing J.L., Nelson S.A., Lee Y.K., Reid J.M., Ames M.M., et al. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clin Cancer Res 11 16 (2005) 5935-5941
152. Byrd J.C., Peterson B.L., Gabrilove J., Odenike O.M., Grever M.R., Rai K., et al. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin Cancer Res 11 11 (2005) 4176-4181
153. Brown J.R. Chronic lymphocytic leukemia: a niche for flavopiridol?. Clin Cancer Res 11 11 (2005) 3971-3973
154. Fuse E., Kuwabara T., Sparreboom A., Sausville E.A., and Figg W.D. Review of UCN-01 development: a lesson in the importance of clinical pharmacology. J Clin Pharmacol 45 4 (2005) 394-403
155. Sausville E.A., Lush R.D., Headlee D., Smith A.C., Figg W.D., Arbuck S.G., et al. Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models. Cancer Chemother Pharmacol 42 Suppl (1998) S54-S59
156. Fuse E., Tanii H., Kurata N., Kobayashi H., Shimada Y., Tamura T., et al. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res 58 15 (1998) 3248-3253
157. Folkman J., Merler E., Abernathy C., and Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 133 2 (1971) 275-288
158. de Castro Junior G., Puglisi F., de Azambuja E., El Saghir N.S., and Awada A. Angiogenesis and cancer: a cross-talk between basic science and clinical trials (the "do ut des" paradigm). Crit Rev Oncol Hematol 59 1 (2006) 40-50
159. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20 21 (2002) 4368-4380
160. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1 1 (1995) 27-31
161. Horstmann E., McCabe M.S., Grochow L., Yamamoto S., Rubinstein L., Budd T., et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 352 9 (2005) 895-904
162. Browder T., Butterfield C.E., Kraling B.M., Shi B., Marshall B., O'Reilly M.S., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60 7 (2000) 1878-1886
163. Goldberg R.M., Hurwitz H.I., and Fuchs C.S. The role of targeted therapy in the treatment of colorectal cancer. Clin Adv Hematol Oncol 4 8 (2006) 1-12 Suppl 17
164. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2 10 (2002) 795-803
165. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7 9 (2001) 987-989
166. Yuan F., Chen Y., Dellian M., Safabakhsh N., Ferrara N., and Jain R.K. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 93 25 (1996) 14765-14770
167. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 5 (2003) 427-434
168. Escudier B., Koralewski P., Pluzanska A., et al. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon-α2a as first-line therapy in metastatic renal cell carcinoma. J Clin Oncol 25 18S (2007) [Abstract 3]
169. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 23 (2004) 2335-2342
170. Giantonio B.J., Catalano P.J., Meropol N.J., O'Dwyer P.J., Mitchell E.P., Alberts S.R., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25 12 (2007) 1539-1544
171. Sandler A.B., Gray R., Brahmer J., et al. Randomized phase II/III trial of paclitaxel plus carboplatin with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer: an Eastern Cooperative Oncology Group (ECOG) Trial-E4599. J Clin Oncol 23 16S Pt1 (2005) 2s [Abstract]
172. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer (MCRC). Abstract 238. 2007 Gastrointestinal cancers symposium; 2007.
173. Los M., Roodhart J.M., and Voest E.E. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 12 4 (2007) 443-450
174. Miller K., Wang M., Gralow J., et al. First-line bevacizumab and paclitaxel in patients with locally recurrent or metastatic breast cancer: a randomized, phase III trial coordinated by the Eastern Cooperative Oncology Group (E2100). Eur J Cancer Suppl 3 (2005) 77-78 [Abstract]
175. Relf M., LeJeune S., Scott P.A., Fox S., Smith K., Leek R., et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57 5 (1997) 963-969
176. Miller K.D., Chap L.I., Holmes F.A., Cobleigh M.A., Marcom P.K., Fehrenbacher L., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 4 (2005) 792-799
177. Karayiannakis A.J., Bolanaki H., Syrigos K.N., Asimakopoulos B., Polychronidis A., Anagnostoulis S., et al. Serum vascular endothelial growth factor levels in pancreatic cancer patients correlate with advanced and metastatic disease and poor prognosis. Cancer Lett 194 1 (2003) 119-124
178. Niedergethmann M., Hildenbrand R., Wostbrock B., Hartel M., Sturm J.W., Richter A., et al. High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 25 2 (2002) 122-129
179. Kindler H.L., Friberg G., Singh D.A., Locker G., Nattam S., Kozloff M., et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23 31 (2005) 8033-8040
180. Kindler HL, Niedzwiecki D, Hollis D, et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303. aBSTRACT 108. 2007 Gastrointestinal cancers symposium; 2007.
181. Ahmad T., and Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 10 18 Pt 2 (2004) 6388S-6392S
182. Awada A., Hendlisz A., Gil T., Bartholomeus S., Mano M., de Valeriola D., et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 92 10 (2005) 1855-1861
183. Strumberg D., Voliotis D., Moeller J.G., Hilger R.A., Richly H., Kredtke S., et al. Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Int J Clin Pharmacol Ther 40 12 (2002) 580-581
184. Ratain M.J., Eisen T., Stadler W.M., Flaherty K.T., Kaye S.B., Rosner G.L., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24 16 (2006) 2505-2512
185. Abou-Alfa G.K., Schwartz L., Ricci S., Amadori D., Santoro A., Figer A., et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24 26 (2006) 4293-4300
186. Llovet J., Ricci S., Mazzaferro V., et al. Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): results of a Phase III randomized placebo-controlled trial (SHARP trial). J Clin Oncol 25 18S (2007) LBA1 [Abstract]
187. Osusky K.L., Hallahan D.E., Fu A., Ye F., Shyr Y., and Geng L. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 7 3 (2004) 225-233
188. Demetri G.D., van Oosterom A.T., Blackstein M., et al. Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients following failure of imatinib for metastatic GIST. J Clin Oncol 23 16S Pt1 (2005) 308s [Abstract]
189. Motzer R.J., Michaelson M.D., Redman B.G., Hudes G.R., Wilding G., Figlin R.A., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 1 (2006) 16-24
190. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 2 (2007) 115-124
191. Herbst R.S., Heymach J.V., O'Reilly M.S., Onn A., and Ryan A.J. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs 16 2 (2007) 239-249
192. Ardizzoni A., and Tiseo M. Combination of target agents: challenges and opportunities. J Thorac Oncol 2 5 Suppl (2007) S4-S6
193. Ryan A.J., and Wedge S.R. ZD6474 - a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br J Cancer 92 Suppl 1 (2005) S6-S13
194. Wedge S.R., Ogilvie D.J., Dukes M., Kendrew J., Chester R., Jackson J.A., et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62 16 (2002) 4645-4655
195. Ciardiello F., Bianco R., Caputo R., Caputo R., Damiano V., Troiani T., et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 10 2 (2004) 784-793
196. Williams K.J., Telfer B.A., Brave S., Kendrew J., Whittaker L., Stratford I.J., et al. ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. Clin Cancer Res 10 24 (2004) 8587-8593
197. Byers L.A., and Heymach J.V. Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer. Clin Lung Cancer 8 Suppl 2 (2007) S79-S85
198. Holden S.N., Eckhardt S.G., Basser R., de Boer R., Rischin D., Green M., et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 16 8 (2005) 1391-1397
199. Natale R., Bodkin D., Govindan R., et al. ZD6474 versus gefitinib in patients with advanced NSCLC: final results from a two-part, double blind, randomized phase II trial. J Clin Oncol 24 (2006) 236s [Abstract]
200. Heymach J.V., Johnson B.E., Prager D., et al. A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: follow-up results. J Clin Oncol 24 (2006) 368s [Abstract]
201. Heymach J.V., West H., Kerr R., et al. ZD6474 in combination with carboplatin and paclitaxel as first-line treatment in patients with NSCLC: results of the run-in phase of a two-part randomized phase II study. Lung Cancer 49 Suppl 2 (2005) S247 [Abstract]
202. Fouladi M. Histone deacetylase inhibitors in cancer therapy. Cancer Invest 24 5 (2006) 521-527
203. Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., and Kelly W.K. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1 3 (2001) 194-202
204. Weidle U.H., and Grossmann A. Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment. Anticancer Res 20 3A (2000) 1471-1485
205. Giles R.H., Peters D.J., and Breuning M.H. Conjunction dysfunction: CBP/p300 in human disease. Trends Genet 14 5 (1998) 178-183
206. Rowley J.D., Reshmi S., Sobulo O., Musvee T., Anastasi J., Raimondi S., et al. All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. Blood 90 2 (1997) 535-541
207. Glaser K.B. HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol (2007)
208. Ueda H., Nakajima H., Hori Y., Fujita T., Nishimura M., Goto T., et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo) 47 3 (1994) 301-310
209. Ueda H., Manda T., Matsumoto S., Mukumoto S., Nishigaki F., Kawamura I., et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J Antibiot (Tokyo) 47 3 (1994) 315-323
210. Ito T., Ouchida M., Morimoto Y., Yoshida A., Jitsumori Y., Ozaki T., et al. Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo. Cancer Lett 224 2 (2005) 311-319
211. Eyupoglu I.Y., Hahnen E., Buslei R., Siebzehnrubl F.A., Savaskan N.E., Luders M., et al. Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo. J Neurochem 93 4 (2005) 992-999
212. Sandor V., Bakke S., Robey R.W., Kang M.H., Blagosklonny M.V., Bender J., et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 8 3 (2002) 718-728
213. Marshall J.L., Rizvi N., Kauh J., Dahut W., Figuera M., Kang M.H., et al. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol 2 6 (2002) 325-332
214. Piekarz R.L., Frye A.R., Wright J.J., Steinberg S.M., Liewehr D.J., Rosing D.R., et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 12 12 (2006) 3762-3773
215. Saito A., Yamashita T., Mariko Y., Nosaka Y., Tsuchiya K., Ando T., et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 96 8 (1999) 4592-4597
216. Butler L.M., Zhou X., Xu W.S., Scher H.I., Rifkind R.A., Marks P.A., et al. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA 99 18 (2002) 11700-11705
217. Mitsiades C.S., Mitsiades N.S., McMullan C.J., Poulaki V., Shringarpure R., Hideshima T., et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 101 2 (2004) 540-545
218. Kelly W.K., O'Connor O.A., Krug L.M., Chiao J.H., Heaney M., Curley T., et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23 17 (2005) 3923-3931
219. Duvic M., Talpur R., Ni X., Zhang C., Hazarika P., Kelly C., et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109 1 (2007) 31-39
220. Hockly E., Richon V.M., Woodman B., Smith D.L., Zhou X., Rosa E., et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci USA 100 4 (2003) 2041-2046
221. Catley L., Weisberg E., Tai Y.T., Atadja P., Remiszewski S., Hideshima T., et al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 102 7 (2003) 2615-2622
222. Zhang Y., Adachi M., Zhao X., Kawamura R., and Imai K. Histone deacetylase inhibitors FK228, N-(2-aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)amino-methyl]benzamide and m-carboxycinnamic acid bis-hydroxamide augment radiation-induced cell death in gastrointestinal adenocarcinoma cells. Int J Cancer 110 2 (2004) 301-308
223. Zhang Y., Jung M., Dritschilo A., and Jung M. Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat Res 161 6 (2004) 667-674
224. Chinnaiyan P., Vallabhaneni G., Armstrong E., Huang S.M., and Harari P.M. Modulation of radiation response by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 62 1 (2005) 223-229
225. Camphausen K., Scott T., Sproull M., and Tofilon P.J. Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation. Clin Cancer Res 10 18 Pt 1 (2004) 6066-6071
226. Emi M., Kim R., Tanabe K., Uchida Y., and Toge T. Targeted therapy against Bcl-2-related proteins in breast cancer cells. Breast Cancer Res 7 6 (2005) R940-R952
227. Huang Z. Bcl-2 family proteins as targets for anticancer drug design. Oncogene 19 56 (2000) 6627-6631
228. Kim R., Tanabe K., Uchida Y., Emi M., Inoue H., and Toge T. Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy. Cancer Chemother Pharmacol 50 5 (2002) 343-352
229. Krajewski S., Krajewska M., Shabaik A., Wang H.G., Irie S., Fong L., et al. Immunohistochemical analysis of in vivo patterns of Bcl-X expression. Cancer Res 54 21 (1994) 5501-5507
230. Hanada M., Aime-Sempe C., Sato T., and Reed J.C. Structure-function analysis of Bcl-2 protein. Identification of conserved domains important for homodimerization with Bcl-2 and heterodimerization with Bax. J Biol Chem 270 20 (1995) 11962-11969
231. Olopade O.I., Adeyanju M.O., Safa A.R., Hagos F., Mick R., Thompson C.B., et al. Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J Sci Am 3 4 (1997) 230-237
232. Miyashita T., and Reed J.C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81 1 (1993) 151-157
233. Gazitt Y., Fey V., Thomas C., and Alvarez R. Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells. Int J Oncol 13 2 (1998) 397-405
234. Furuya Y., Krajewski S., Epstein J.I., Reed J.C., and Isaacs J.T. Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin Cancer Res 2 2 (1996) 389-398
235. Lipponen P., and Vesalainen S. Expression of the apoptosis suppressing protein bcl-2 in prostatic adenocarcinoma is related to tumor malignancy. Prostate 32 1 (1997) 9-15
236. Herbst R.S., and Frankel S.R. Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer. Clin Cancer Res 10 12 Pt 2 (2004) 4245s-4248s
237. Klasa R.J., Gillum A.M., Klem R.E., and Frankel S.R. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 12 3 (2002) 193-213
238. Lopes de Menezes D.E., and Mayer L.D. Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. Cancer Chemother Pharmacol 49 1 (2002) 57-68
239. Rudin C.M., Kozloff M., Hoffman P.C., Edelman M.J., Karnauskas R., Tomek R., et al. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol 22 6 (2004) 1110-1117
240. O'Connor O.A., Smith E.A., Toner L.E., Teruya-Feldstein J., Frankel S., Rolfe M., et al. The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide. Clin Cancer Res 12 9 (2006) 2902-2911
241. Ramanarayanan J., Hernandez-Ilizaliturri F.J., Chanan-Khan A., and Czuczman M.S. Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab. Br J Haematol 127 5 (2004) 519-530
242. Waters J.S., Webb A., Cunningham D., Clarke P.A., Raynaud F., di Stefano F., et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 18 9 (2000) 1812-1823
243. Leonard J.P., Coleman M., Vose J., et al. Phase II study of oblimersen sodium (G3139) alone and with R-CHOP in mantle cell lymphoma (MCL). Proc Am Soc Clin Oncol (2003) 22 [Abstract 2276]
244. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., et al. Identification of human brain tumour initiating cells. Nature 432 7015 (2004) 396-401
245. Richardson G.D., Robson C.N., Lang S.H., Neal D.E., Maitland N.J., and Collins A.T. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 117 Pt 16 (2004) 3539-3545
246. Bonnet D., and Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3 7 (1997) 730-737
247. Yilmaz O.H., Valdez R., Theisen B.K., Guo W., Ferguson D.O., Wu H., et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441 7092 (2006) 475-482
248. Dick J.E. Breast cancer stem cells revealed. Proc Natl Acad Sci USA 100 7 (2003) 3547-3549
249. O'Brien C.A., Pollett A., Gallinger S., and Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445 7123 (2007) 106-110
250. Li C., Heidt D.G., Dalerba P., Burant C.F., Zhang L., Adsay V., et al. Identification of pancreatic cancer stem cells. Cancer Res 67 3 (2007) 1030-1037
251. Hendrix M.J., Seftor E.A., Seftor R.E., Kasemeier-Kulesa J., Kulesa P.M., and Postovit L.M. Reprogramming metastatic tumour cells with embryonic microenvironments. Nat Rev Cancer 7 4 (2007) 246-255
252. Sledge Jr. G.W. What is targeted therapy?. J Clin Oncol 23 8 (2005) 1614-1615
253. Fearon E.R., and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61 5 (1990) 759-767
254. Bild A.H., Yao G., Chang J.T., Wang Q., Potti A., Chasse D., et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439 7074 (2006) 353-357
255. Parulekar W.R., and Eisenhauer E.A. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J Natl Cancer Inst 96 13 (2004) 990-997
256. Davis D.W., McConkey D.J., Abbruzzese J.L., and Herbst R.S. Surrogate markers in antiangiogenesis clinical trials. Br J Cancer 89 1 (2003) 8-14
257. Rosa D.D., Clamp A.R., Collinson F., and Jayson G.C. Antiangiogenic therapy for ovarian cancer. Curr Opin Oncol 19 (2007) 497-505
258. Sica D.A. Angiogenesis inhibitors and hypertension: an emerging issue. J Clin Oncol 24 9 (2006) 1329-1331
259. Kelloff G.J., and Sigman C.C. New science-based endpoints to accelerate oncology drug development. Eur J Cancer 41 4 (2005) 491-501
260. Dagher R., Johnson J., Williams G., Keegan P., and Pazdur R. Accelerated approval of oncology products: a decade of experience. J Natl Cancer Inst 96 20 (2004) 1500-1509
261. Lengauer C., Diaz Jr. L.A., and Saha S. Cancer drug discovery through collaboration. Nat Rev Drug Discov 4 5 (2005) 375-380
262. Benson J.D., Chen Y.N., Cornell-Kennon S.A., Dorsch M., Kim S., Leszczyniecka M., et al. Validating cancer drug targets. Nature 441 7092 (2006) 451-456